Previous 10 | Next 10 |
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
HQH has a strong and steady dividend history, supported by its earnings. HQH’s stock has performed poorly over the past 5 years, but over the long run it has generated stable price growth. Current price multiples and NAV indicates HQH is trading at a discount. For fur...
FHLC is a well-diversified healthcare ETF concentrated on large caps. FHLC generated strong return, and closely replicated returns of S&P 500. FHLC has strong price multiples and financial growth, at par with peers. For further details see: FHLC: Well Diversified, St...
The U.S. Food and Drug Administration (FDA) granted priority review to Horizon Therapeutics' (NASDAQ:HZNP) biologics license application to expand the label for Krystexxa plus methotrexate. The FDA is expected to make a decision by July 7. Krystexxa is indicated for treating chronic...
The FDA has placed a partial clinical hold on a phase 2 trial of Alpine Immune Sciences' (NASDAQ:ALPN) davoceticept for advanced malignancies following a patient death. The company said the participant had received a single dose each of davoceticept and Keytruda (pembrolizumab). The caus...
-- sBLA seeks to expand the label to include KRYSTEXXA plus methotrexate to help more patients achieve a complete and durable response to therapy -- -- Application based on recent MIRROR randomized controlled trial results, which showed 71% of patients randomized to receive KR...
John Paulson’s 13F portfolio value decreased from $3.51B to $3.24B this quarter. Paulson & Company increased Pacira Biosciences and SSR mining while reducing Brightsphere Investment Group and Thryv Holdings. The top three positions are at 49% of the portfolio. For...
-- The “NMOSD Won’t Stop Me” initiative aims to bring the community together through storytelling during NMO Awareness Month and beyond -- Horizon Therapeutics plc (Nasdaq: HZNP) is teaming up with Christine Ha, the first blind contestant on MasterChef a...
The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with their 2021 Q4 earnings call. For further details see: Horizon Therapeutics Public Limited Company 2021 Q4 - Results - Earnings Call Presentation
My portfolio, built specifically for my retirement ~20+ years from now, experiences some major shifts as I play for upside in oil and former market darlings. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helpi...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...